HKPD vs RGNT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HKPD presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive growth momentum. While the company maintains a strong liquidity position with a current ratio of 2.93 and low debt, these strengths are overshadowed by a severe collapse in fundamentals, including a 35.7% YoY revenue decline and an 83.1% drop in earnings. The technical trend is purely bearish (0/100), and the stock has lost nearly 78% of its value over the last five years, indicating a long-term structural decline.
RGNT exhibits severe financial distress characterized by a weak Piotroski F-Score of 3/9 and a complete absence of revenue. The company's ROA of -107.53% indicates massive capital erosion, while the stock price has collapsed by 61.7% over the last year. Despite a decent current ratio of 2.65, the lack of operational viability and a 0/100 technical trend suggest a high-risk speculative profile. The single analyst target of $10.00 is disconnected from the current fundamental reality.
Compare Another Pair
Related Comparisons
HKPD vs RGNT: Head-to-Head Comparison
This page compares Cellyan Biotechnology Co., Ltd (HKPD) and Regentis Biomaterials Ltd. (RGNT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.